<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">37312136</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-684X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>BMC palliative care</Title><ISOAbbreviation>BMC Palliat Care</ISOAbbreviation></Journal><ArticleTitle>Quality of life and depression in patients with amyotrophic lateral sclerosis - does the country of origin matter?</ArticleTitle><Pagination><StartPage>72</StartPage><MedlinePgn>72</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">72</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12904-023-01189-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Given the inevitable relentless progressing nature of amyotrophic lateral sclerosis (ALS), it is essential to identify factors influencing patients' wellbeing. The study aimed to prospectively assess factors influencing the quality of life (QoL) and depression in ALS patients compared to healthy controls (HCs) from Poland, Germany and Sweden and their relationship to socio-demographic and clinical factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">314 ALS patients (120 from Poland, 140 from Germany, 54 from Sweden) and 311 age-, sex- and education-level-matched HCs underwent standardized interviews for quality of life, depression, functional status and pain.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients from all three countries showed similar levels of functional impairment (ALSFRS-R). Overall, ALS patients assessed their quality of life as lower compared to HCs (p&#x2009;&lt;&#x2009;0.001 for the anamnestic comparative self-assessment (ACSA), p&#x2009;=&#x2009;0.002 for the Schedule for the evaluation of the subjective quality of life - SEIQoL- direct weighting (SEIQoL-DW). Also, the German and Swedish patients, but not the Polish, reported higher depression levels than the corresponding HCs (p&#x2009;&lt;&#x2009;0.001). Analysis of ALS groups revealed that functional impairment was related to a lower quality of life (ACSA) and higher depression levels among German ALS patients. Longer time since diagnosis predicted lower depression and (in male subjects) higher quality of life.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ALS patients assess their quality of life and mood lower than healthy individuals within the studied countries. The relationships between clinical and demographic factors are moderated by country of provenance, which bears implications for the design and interpretation of scientific and clinical studies, which should reflect the complexity and heterogeneity of mechanisms determining QoL.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cie&#x107;wierska</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Clinical Center of Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lul&#xe9;</LastName><ForeName>Doroth&#xe9;e</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bielecki</LastName><ForeName>Maksymilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, SWPS University of Social Sciences and Humanities, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helczyk</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maksymowicz-&#x15a;liwi&#x144;ska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Clinical Center of Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finsel</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niepor&#x119;cki</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Clinical Center of Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Institute of Clinical Sciences, Neuroscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku&#x17a;ma-Kozakiewicz</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Clinical Center of Medical University of Warsaw, Warsaw, Poland. mkuzma@wum.edu.pl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Warsaw, Warsaw, Poland. mkuzma@wum.edu.pl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Group, Medical University of Warsaw, Warsaw, Poland. mkuzma@wum.edu.pl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JPND; 01ED1405</GrantID><Agency>EU Joint Program - Neurodegenerative Disease Research project</Agency><Country/></Grant><Grant><GrantID>JPND; 01ED1405</GrantID><Agency>EU Joint Program - Neurodegenerative Disease Research project</Agency><Country/></Grant><Grant><GrantID>JPND; 01ED1405</GrantID><Agency>EU Joint Program - Neurodegenerative Disease Research project</Agency><Country/></Grant><Grant><GrantID>LU 336/13-2 BI 195/54-2</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>LU 336/13-2 BI 195/54-2</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>LU 336/13-2 BI 195/54-2</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>3/IV/MAXOMOD/11.2020</GrantID><Agency>ERA-NET-E Rare</Agency><Country/></Grant><Grant><GrantID>3/IV/MAXOMOD/11.2020</GrantID><Agency>ERA-NET-E Rare</Agency><Country/></Grant><Grant><GrantID>KAW #2014.0305</GrantID><Agency>the Knut and Alice Wallenberg Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Palliat Care</MedlineTA><NlmUniqueID>101088685</NlmUniqueID><ISSNLinking>1472-684X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Pain</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Wellbeing</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37312136</ArticleId><ArticleId IdType="pmc">PMC10262126</ArticleId><ArticleId IdType="doi">10.1186/s12904-023-01189-2</ArticleId><ArticleId IdType="pii">10.1186/s12904-023-01189-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahrendt D, Dubois H, Mezger E. (2015). An overview of quality of life in Europe. Global handbook of quality of life, 625&#x2013;661.</Citation></Reference><Reference><Citation>Alca&#xf1;iz M, Sol&#xe9;-Aur&#xf3; A. Feeling good in old age: factors explaining health-related quality of life. Health Qual Life Outcomes Mar. 2018;13(1):48. doi: 10.1186/s12955-018-0877-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-018-0877-z</ArticleId><ArticleId IdType="pmc">PMC5851254</ArticleId><ArticleId IdType="pubmed">29534708</ArticleId></ArticleIdList></Reference><Reference><Citation>Alencar MA, da Silva IMM, Hil&#xe1;rio SM, de Andrade Rangel MF, Abdo JS, Ara&#xfa;jo CM, Souza LC. Quality of life, disability, and clinical variables in amyotrophic lateral sclerosis. Arq Neuropsiquiatr. 2022;80(3):255&#x2013;61. doi: 10.1590/0004-282X-ANP-2021-0201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0004-282X-ANP-2021-0201</ArticleId><ArticleId IdType="pmc">PMC9648935</ArticleId><ArticleId IdType="pubmed">34932653</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360&#x2013;75. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Ku&#x17a;ma-Kozakiewicz M, Keller J, Aho-Oezhan HEA, Ciecwierska K, et al. Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. J Neurol. 2018;265(7):1600&#x2013;6. doi: 10.1007/s00415-018-8861-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8861-4</ArticleId><ArticleId IdType="pubmed">29728768</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Cook A, Pineda CM, Yerramilli-Rao P, Pulley D, Cudkowicz M. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12(2):109&#x2013;12. doi: 10.3109/17482968.2010.536839.v.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.536839.v</ArticleId><ArticleId IdType="pmc">PMC3155886</ArticleId><ArticleId IdType="pubmed">21091399</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernheim JL. How to get serious answers to the serious question:&#x2018;How have you been?&#x2019;: subjective quality of life (QOL) as an individual experiential emergent construct. Bioethics. 1999;13(3&#x2013;4):272&#x2013;87. doi: 10.1111/1467-8519.00156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1467-8519.00156</ArticleId><ArticleId IdType="pubmed">11657238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernheim JL, Theuns P, Mazaheri M, et al. The potential of Anamnestic Comparative Self-Assessment (ACSA) to Reduce Bias in the measurement of Subjective Well-Being. J Happiness Stud. 2006;7:227&#x2013;50. doi: 10.1007/s10902-005-4755-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10902-005-4755-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases: El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;9. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function, BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Gauthier A, Montuschi A, Calvo A, Di Vito N, Ghiglione P, Mutanii R. A cross sectional study on determinants of quality of life in ALS. J Neurol Neurosurg Psychiatry. 2004;75:1597&#x2013;601. doi: 10.1136/jnnp.2003.033100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.033100</ArticleId><ArticleId IdType="pmc">PMC1738825</ArticleId><ArticleId IdType="pubmed">15489393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. (1988). Statistical Power Analysis for the Social Sciences (2nd. Edition). Hillsdale, New Jersey, Lawrence Erlbaum Associates. 10.4324/9780203771587.</Citation></Reference><Reference><Citation>Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149&#x2013;60. doi: 10.3758/BRM.41.4.1149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/BRM.41.4.1149</ArticleId><ArticleId IdType="pubmed">19897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Felgoise SH, Stewart JL, Bremer BA, Walsh SM, Bromberg MB, Simmons Z. The SEIQoL-DW for assessing quality of life in ALS: strengths and limitations. Amyotroph Lateral Scler. 2009;10:456&#x2013;62. doi: 10.3109/17482960802444840.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802444840</ArticleId><ArticleId IdType="pubmed">19922140</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley G, Timonen V, Hardiman O. Acceptance and decision making in amyotrophic lateral sclerosis from a life-course perspective. Qual Health Res. 2014;24(1):67&#x2013;77. doi: 10.1177/1049732313516545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049732313516545</ArticleId><ArticleId IdType="pubmed">24336481</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsgren L, Almay BG, Holmgren G, Wall S, Acta Neurol, Scand, Forsgren L, Almay BG, Holmgren G, Wall S. (1983). Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand, 68(1):20 &#x2013; 9. 10.1111/j.1600-0404.1983.tb04810.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">6604389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer EM, H&#xe4;cker S, Hautzinger M, Meyer TD, K&#xfc;bler A. Validity of the ALS-Depression-inventory (ADI-12)--a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord. 2008;109(1&#x2013;2):213&#x2013;9. doi: 10.1016/j.jad.2007.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2007.11.012</ArticleId><ArticleId IdType="pubmed">18262283</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo Y-A. (2022). Sodium Phenylbutyrate and Ursodoxicoltaurine: first approval, CNS drugs, Jul 30. 10.1007/s40263-022-00945-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">35907175</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey AM, Bury G, O&#x2019;Boyle CA, Bradley F, O&#x2019;Kelly FD, Shannon W. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. The BMJ. 1996;313(7048):29&#x2013;33. doi: 10.1136/bmj.313.7048.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.313.7048.29</ArticleId><ArticleId IdType="pmc">PMC2351443</ArticleId><ArticleId IdType="pubmed">8664768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoin MC. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;55. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Kollewe K, Abdulla S, Zapf A, Dengler R, Petri S. Interaction of physical function, quality of life and depression in Amyotrophic lateral sclerosis: characterization of a large patient cohort. BMC Neurol. 2015 doi: 10.1186/s12883-015-0340-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-015-0340-2</ArticleId><ArticleId IdType="pmc">PMC4493831</ArticleId><ArticleId IdType="pubmed">25982050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, H&#xe4;cker S, Ludolph A, Birbaumer N, K&#xfc;bler A. Depression and quality of life in patients with amyotrophic lateral sclerosis. Dtsch Arztebl Int. 2008;105(23):397&#x2013;403. doi: 10.3238/arztebl.2008.0397.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2008.0397</ArticleId><ArticleId IdType="pmc">PMC2696844</ArticleId><ArticleId IdType="pubmed">19626161</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Zickler C, H&#xe4;cker S, Bruno MA, Demertzi A, Pellas F, Laureys S, K&#xfc;bler A. Life can be worth living in Locked-In syndrome. Prog Brain Res. 2009;177:339&#x2013;51. doi: 10.1016/S0079-6123(09)17723-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0079-6123(09)17723-3</ArticleId><ArticleId IdType="pubmed">19818912</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Ehlich B, Lang D, Sorg S, Heimrath J, K&#xfc;bler A, Birbaumer N, Ludolph AC. Quality of life in fatal disease: the flawed judgement of the social environment. J Neurol. 2013;260(11):2836&#x2013;43. doi: 10.1007/s00415-013-7068-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-7068-y</ArticleId><ArticleId IdType="pubmed">23989341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Nonnenmacher S, Sorg S, Heimrath J, Hautzinger M, Meyer T, K&#xfc;bler A, Birbaumer N, Ludolph AC. Live and let die: existential decision processes in a fatal disease. J Neurol. 2014;261(3):518&#x2013;25. doi: 10.1007/s00415-013-7229-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-7229-z</ArticleId><ArticleId IdType="pubmed">24413639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, K&#xfc;bler A, Ludolph AC. Ethical principles in patient-centered Medical Care to support quality of life in amyotrophic lateral sclerosis. Front Neurol. 2019;10:259. doi: 10.3389/fneur.2019.00259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00259</ArticleId><ArticleId IdType="pmc">PMC6439311</ArticleId><ArticleId IdType="pubmed">30967833</ArticleId></ArticleIdList></Reference><Reference><Citation>Medrano CRV, Aho-&#xd6;zhan H, Weiland U, Uttner I, Ludolph AC, Lul&#xe9; D. Disease progression but not physical state per se determines mental wellbeing in ALS. J Neurol. 2020;267:3593&#x2013;601. doi: 10.1007/s00415-020-10027-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10027-x</ArticleId><ArticleId IdType="pmc">PMC7674363</ArticleId><ArticleId IdType="pubmed">32638110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet. 2007;369:2031&#x2013;41. doi: 10.1016/S0140-6736(07)60944-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60944-1</ArticleId><ArticleId IdType="pubmed">17574095</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern&#xe1;ndez M, Mar&#xed;n S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O. AB10015 STUDY GROUP, Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1&#x2013;2):5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Neudert C, Wasner M, Borasio GD. Patients&#x2019; assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001;191(1&#x2013;2):103&#x2013;9. doi: 10.1016/s0022-510x(01)00612-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(01)00612-8</ArticleId><ArticleId IdType="pubmed">11676999</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, An J, Park K. Coping in people with amyotrophic lateral sclerosis and motor neuron disease: systematic review. J Clin Nurs. 2021;30(13&#x2013;14):1838&#x2013;53. doi: 10.1111/jocn.15692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocn.15692</ArticleId><ArticleId IdType="pubmed">33555628</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerramilli-Rao P, Cudkowicz M, Atassi N. Functional decline is Associated with hopelessness in amyotrophic lateral sclerosis. J Neurol Neuropsychol. 2017;8(2). 10.4172/2155-9562.1000423. Sherman A .Atassi H.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5548143</ArticleId><ArticleId IdType="pubmed">28798889</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagnini F, Banfi LCh, Rossi P, Fossati G, Marconi F, Castelnuovo A, Corbo G, Molinari M. Pain in Amyotrophic lateral sclerosis: a psychological perspective. Neurol Sci. 2012;33:1193&#x2013;6. doi: 10.1007/s10072-011-0888-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-011-0888-6</ArticleId><ArticleId IdType="pubmed">22183268</ArticleId></ArticleIdList></Reference><Reference><Citation>Peseschkian T, Cordts I, G&#xfc;nther R, Stolte B, et al. A Nation-Wide, multi-center study on the quality of life of ALS Patients in Germany. Brain Sci. 2021;14(3):372. doi: 10.3390/brainsci11030372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11030372</ArticleId><ArticleId IdType="pmc">PMC7998410</ArticleId><ArticleId IdType="pubmed">33799476</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team . R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.</Citation></Reference><Reference><Citation>Rabkin JG, Wagner GJ, Del Bene M. Resilience and distress among amyotrophic lateral sclerosis patients and caregivers. Psychosom Med. 2000;62:271&#x2013;9. doi: 10.1097/00006842-200003000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006842-200003000-00020</ArticleId><ArticleId IdType="pubmed">10772408</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of life in ALS is maintained as physical function declines. Neurology. 2001;56:442&#x2013;4. doi: 10.1212/wnl.56.4.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.56.4.442</ArticleId><ArticleId IdType="pubmed">11222784</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrempf T, Finsel J, Uttner I, Ludolph AC, Lul&#xe9; D. Neuropsychological deficits have only limited impact on psychological well-being in amyotrophic lateral sclerosis. J Neurol. 2022;269:1369&#x2013;74. doi: 10.1007/s00415-021-10690-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10690-8</ArticleId><ArticleId IdType="pmc">PMC8857089</ArticleId><ArticleId IdType="pubmed">34215919</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshiri H, Fatehi F, Abolfazli R, Harirchian MH, Sedighi B, Zamani B, Roudbari A, Razazian N, Khamseha F, Nafiss S. Trends of quality of life changes in amyotrophic lateral sclerosis patients. J Neurol Sci. 2016;368:35&#x2013;40. doi: 10.1016/j.jns.2016.06.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.06.056</ArticleId><ArticleId IdType="pubmed">27538598</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z, Bremer BA, Robbins RA, Walsh SM, Fischer S. Quality of life in ALS depends on factors other than strength and physical function. Neurology. 2000;55:388&#x2013;92. doi: 10.1212/wnl.55.3.388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.55.3.388</ArticleId><ArticleId IdType="pubmed">10932273</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojka P, Andersen PM, Forsgren L. Effects of riluzole on symptom progression in amyotrophic lateral sclerosis. Lancet. 1997;349(9046):176&#x2013;7. doi: 10.1016/s0140-6736(05)60977-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(05)60977-4</ArticleId><ArticleId IdType="pubmed">9111546</ArticleId></ArticleIdList></Reference><Reference><Citation>Stordal E, Mykletun A, Dahl AA. The association between age and depression in the general population: a multivariate examination. Acta Psychiatr Scand. 2003;107(2):132&#x2013;41. doi: 10.1034/j.1600-0447.2003.02056.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0447.2003.02056.x</ArticleId><ArticleId IdType="pubmed">12534439</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Bedlack R, Armon C, Beauchamp M, Bertorini T, Bowser R, Bromberg M, Caress J, Carter G, Crayle J, Cudkowicz ME, Glass JD, Jackson C, Lund I, Martin S, Paganoni S, Pattee G, Ratner R, Salmon K, Wicks P. ALSUntangled #64: butyrates. Amyotroph Lateral Scler Frontotemporal Degener. 2022;28:1&#x2013;6. doi: 10.1080/21678421.2022.2045323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2022.2045323</ArticleId><ArticleId IdType="pubmed">35225121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wettergren L, Kettis-Lindblad A, Sprangers M, Ring L. The use, feasibility and psychometric properties of an individualised quality-of-life instrument: a systematic review of the SEIQoL-DW. Qual Life Res Aug. 2009;18(6):737&#x2013;46. doi: 10.1007/s11136-009-9490-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-009-9490-2</ArticleId><ArticleId IdType="pubmed">19496021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojciszke B. The negative social world: the polish culture of complaining. Int J Sociol. 2004;34(4):38&#x2013;59. doi: 10.1080/00207659.2004.11043140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207659.2004.11043140</ArticleId></ArticleIdList></Reference><Reference><Citation>WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):20&#x2013;31. doi: 10.1080/21678421.2017.1362000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1362000</ArticleId><ArticleId IdType="pubmed">28872918</ArticleId></ArticleIdList></Reference><Reference><Citation>WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation) Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):40&#x2013;8. doi: 10.1080/21678421.2017.1361441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361441</ArticleId><ArticleId IdType="pubmed">28872915</ArticleId></ArticleIdList></Reference><Reference><Citation>www.NEEDSinALS.com.</Citation></Reference><Reference><Citation>V&#xe1;zquez MC, Aho-&#xd6;zhan H, Weiland U, Uttner I, Ludolph AC, Lul&#xe9; D. Disease progression but not physical state per se determines mental wellbeing in ALS. J Neurol. 2020;267(12):3593&#x2013;601. doi: 10.1007/s00415-020-10027-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10027-x</ArticleId><ArticleId IdType="pmc">PMC7674363</ArticleId><ArticleId IdType="pubmed">32638110</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19(3):185&#x2013;93. doi: 10.1080/14737175.2019.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2019.1</ArticleId><ArticleId IdType="pubmed">30810406</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>